Holen Sie sich die Stockscreener-App
2.49
2.26%
0.055
Schlusskurs vom Vortag:
$2.435
Offen:
$2.48
24-Stunden-Volumen:
961.23K
Relative Volume:
0.95
Marktkapitalisierung:
$202.34M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-78.15M
KGV:
-2.9045
EPS:
-0.8573
Netto-Cashflow:
$-68.89M
1W Leistung:
-6.04%
1M Leistung:
-16.72%
6M Leistung:
-18.89%
1J Leistung:
-9.78%
1-Tages-Spanne:
$2.42
$2.55
1-Wochen-Bereich:
$2.42
$2.66
52-Wochen-Spanne:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Firmenname
Eledon Pharmaceuticals Inc
Sektor
Branche
Telefon
949-238-8090
Adresse
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.49 | 215.34M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Guggenheim | Buy |
| 2022-05-13 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-03-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Eledon Pharmaceuticals (ELDN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026Slideshow (NASDAQ:ELDN) 2026-09-22 - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Shares Rise on Positive Tegoprubar - GuruFocus
Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ) - Seeking Alpha
Eledon Gains 13% on Updated Phase 2 Trial Data - Orange County Business Journal
Eledon Pharmaceuticals (ELDN) Advances Tegoprubart Trials with F - GuruFocus
Eledon Pharmaceuticals, Inc. (ELDN) stock price, news, quote and history - uk.finance.yahoo.com
Eledon’s tegoprubart shows kidney function advantage in phase 2 trial - Investing.com
Eledon’s tegoprubart shows kidney function advantage in phase 2 trial By Investing.com - Investing.com India
No reported rejections followed Eledon’s drug after six months, versus seven for tacrolimus. Phase 3 is expected in Q4 2026. - Stock Titan
ELDN Should I Buy - intellectia.ai
A treatment to prevent kidney transplant rejection will be presented Sept. 22 - Stock Titan
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - The Manila Times
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon submits IND for tegoprubart islet cell transplant study By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Submits IND Application to US FDA for Tegoprubart - marketscreener.com
Eledon submits IND for tegoprubart islet cell transplant study - investing.com
12 people with type 1 diabetes no longer needed insulin after transplants. Three more are joining. - Stock Titan
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - The Manila Times
Eledon Pharmaceuticals (ELDN) Slips 3.6% to $3.2, Holding Between Support and ResistanceNAAIM Leverage - dars.gov.et
Eledon Pharmaceuticals (ELDN) Retreats 3.6% to $3.2 Amid Biotech Selling PressureMerger Arbitrage - vinanet.vn
Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen - MarketBeat
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Breakout Confirmation - vinanet.vn
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals (ELDN) - Zacks Investment Research
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Eledon Q2 EPS misses estimates as net loss widens 182% YoY - scanx.trade
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3 - Stock Titan
Eledon Islet Study: All 12 Patients Reached Insulin Independence - Stock Titan
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Meets Mild Share UptickInterim Report - vinanet.vn
Eledon Pharmaceuticals (ELDN) Holds Above $3.60 Support After Modest AdvanceAnchored VWAP - vinanet.vn
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEPS Surprise History - careplusvn.com
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Eledon Pharmaceuticals (ELDN) Institutional Ownership 2026 - MarketBeat
Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday - MarketBeat
ELDN Q2'26 Earnings: EPS estimate is (0.16) USD - TradingView
Eledon Pharmaceuticals (ELDN) Gains 2.19% as Shares Trade Between Key LevelsMoving Average Ribbon - careplusvn.com
Eledon Pharmaceuticals Inc. (ELDN) Q1 2026 Earnings: EPS Misses Estimates by 77.23% as Stock Declines - dars.gov.et
Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADAR1 Capital Management LLC Has $3 Million Position in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
Eledon Pharmaceuticals Inc (ELDN) Cash Flow - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELDN - TradingView
Finanzdaten der Eledon Pharmaceuticals Inc-Aktie (ELDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Eledon Pharmaceuticals Inc-Aktie (ELDN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hillson Jan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Kirk Allan | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Katkin Keith | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
8,575 |
0 |
8,575 |
| Lee June | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
| Robinson James A. Jr. | Director |
Jan 10 '26 |
Option Exercise |
0.00 |
3,430 |
0 |
3,430 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):